Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Scientists from the University of Pennsylvania developed a new approach to address fibrosis, a leading cause of heart disease.
Absci Corporation inked a deal with Merck. Absci will leverage its Bionic Protein non-standard amino acid technology and AI-integrated Drug Creation Platform to create enzymes for Merck.
A research team out of MIT may have found a surprising causal aspect of Down syndrome that’s worth further investigation.
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
On Friday morning, AstraZeneca’s rare disease group Alexion and Switzerland-based Neurimmune entered into a collaboration and licensing agreement for NI006.
Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.
Judge Mark Pittman found that the Freedom of Information Act filed by PHMPT is of paramount public importance and demands that the FDA make the data publicly available within eight months.
As the Omicron strain sweeps the world, researchers rush to determine how effective vaccines are at creating immunity against the variant. For that and more, continue reading.
Over the past ten years, Tonix’s pipeline has evolved to also comprise assets in biodefense, immunology and cancer therapeutics.
He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
PRESS RELEASES
• ASCO 2026: 2.5-Year Overall Survival Data • Jefferies Healthcare Conference: Partnering & Investor meetings • BIO International Convention: Panel Participation • MIB Agents Factor Osteosarcoma Conference: Data Presentation
The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia’s Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025
Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT
• MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSanteTM. • Based on infield grower data, the mustard-derived TerraSanteTM biofertility product has been shown to improve crop yields, soil, and potentially the soil microbiome health for nutrient/water use efficiencies.
· Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of MetrioPharm AG. · With more than 800 peer-reviewed publications and various prestigious awards, Prof. Braun is internationally recognized as a leading expert in the field of modern clinical and academic rheumatology.
Pharmaceutical service provider receives prestigious management award for the seventh year in a row · Family-owned company once again excels in all four key business areas · Site development and digitalization as strategic investment priorities · Focus on new sources for skilled workers and on lifelong learning
The upgraded platform offers a searchable database of over 300 risk-assessed HCPs, automated research scanning, and new flexible pricing options for mid-size drug developers.
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging